44 afleveringen

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education

    • Wetenschap

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Jay B. Wish, MD / Daniel W. Coyne, MD / Chilnille L. Milbrooks, MSN, FNP-C - Evolving Management Approaches to Anemia in Chronic Kidney Disease: Implications for the Nephrology Nurse

    Jay B. Wish, MD / Daniel W. Coyne, MD / Chilnille L. Milbrooks, MSN, FNP-C - Evolving Management Approaches to Anemia in Chronic Kidney Disease: Implications for the Nephrology Nurse

    Go online to PeerView.com/MVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of experts offers insight into best practices regarding the treatment of anemia associated with chronic kidney disease (CKD) and emphasizes that the success of employing current (and future) treatments falls on the members of the interdisciplinary nephrology care team. Foundational guidance is combined with a discussion of real cases to further highlight new developments in the management of anemia associated with CKD and provide practical guidance on the integration of such advances. Upon completion of this activity, participants will be able to: Describe the prevalence, clinical impact, and pathogenesis of anemia in CKD, Identify benefits and limitations associated with current management approaches to anemia in CKD, Recognize the mechanism of action of emerging hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in the management of anemia in CKD, Assess safety and efficacy data supporting HIF-PH inhibitor use in patients with anemia in CKD, Employ strategies to treat anemia in CKD in accordance with current evidence, expert recommendations, and individual patient needs.

    • 1 u. 14 min.
    • video
    Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN - Visualizing the Potential Role of HIF-PH Inhibitors in the Treatment of Anemia in Chronic Kidney Disease

    Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN - Visualizing the Potential Role of HIF-PH Inhibitors in the Treatment of Anemia in Chronic Kidney Disease

    Go online to PeerView.com/KMS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic kidney disease (CKD) discusses anemia in CKD and explores the potential role of HIF-PH inhibitors in the treatment of this condition. Upon completion of this activity, participants will be able to: Identify the epidemiology, pathology, and burden of anemia associated with CKD, Discuss limitations of the current model of treatment for anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the benefits and limitations of current and emerging agents to treat anemia in CKD.

    • 20 min.
    • video
    Kenneth C. Kalunian, MD / Maureen A. McMahon, MD / Joan T. Merrill, MD - Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient

    Kenneth C. Kalunian, MD / Maureen A. McMahon, MD / Joan T. Merrill, MD - Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient

    Go online to PeerView.com/YHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME video activity, experts in systemic lupus erythematosus (SLE) give a detailed discussion on the autoimmune disease, providing guidance on recognizing the clinical features and confirming a diagnosis, as well as contemporary strategies to manage diverse disease manifestations. Hear what the experts are doing in their clinics. Upon completion of this activity, participants should be better able to: Identify systemic lupus erythematosus (SLE) as a heterogeneous autoimmune disease with a wide range of clinical and serological manifestations that can affect any organ, Employ appropriate criteria to confirm a diagnosis of SLE, recognizing the clinical utility of available classification systems, Utilize evidence-based tools to monitor disease activity in individual SLE patients in daily clinical practice and guide treatment decisions, Describe current treatment options for SLE according to mechanism of action, efficacy, safety, and impact on patient symptoms/quality of life, Develop treatment plans for individual patients with SLE to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage, Effectively communicate and collaborate with SLE patients and other care providers to understand and address the needs of each patient and maximize treatment adherence, quality of life, and survival outcomes.

    • 1 u. 11 min.
    • video
    John B. Buse, MD, PhD - Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases

    John B. Buse, MD, PhD - Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases

    Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

    • 1 u. 16 min.
    • video
    George D. Demetri, MD - Modern Diagnostics and Targeted Therapy for TRK Fusion Cancers: Pathology-Oncologist Collaboration in the Era of Precision Medicine

    George D. Demetri, MD - Modern Diagnostics and Targeted Therapy for TRK Fusion Cancers: Pathology-Oncologist Collaboration in the Era of Precision Medicine

    Go online to PeerView.com/DMK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this new CME/MOC/CC activity, an expert panel discusses the diagnosis and management ofNTRK gene fusion-positive cancers. Throughout this video, the panelists explore the diagnostic consensus for capturing gene fusions, and describe how pathologists and oncologists can collaborate to rapidly identify patients with TRK fusion cancers and recommend appropriate therapy options. Upon completion of this activity, participants should be better able to: Cite the current diagnostic and treatment consensus for adult and pediatric patients with TRK fusion cancers, Summarize the latest efficacy and safety data on the use of TRK inhibitors in patients with NTRK fusion-positive cancers, Employ effective diagnostic techniques for confirming the presence of NTRK fusions in solid tumors, Integrate TRK inhibitors into the management of NTRK fusion-positive tumors based on results of diagnostic testing, including for diseases such as lung, breast, and gastrointestinal cancers, among others.

    • 1 u. 11 min.
    • video
    Georgine Lamvu, MD, MPH - Current and Emerging Therapies for Endometriosis and Uterine Fibroids: What Do You Need to Know?

    Georgine Lamvu, MD, MPH - Current and Emerging Therapies for Endometriosis and Uterine Fibroids: What Do You Need to Know?

    Go online to PeerView.com/ZYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in women’s health discusses current and emerging therapies for endometriosis and uterine fibroids. Upon completion of this activity, participants should be better able to: Summarize the diagnostic evaluation for uterine fibroids and endometriosis including ultrasound, lab tests and other imaging tests, Recognize the benefits and limitations of current and emerging options for medical management of endometriosis and uterine fibroids, Discuss recent clinical data for the management of endometriosis-associated pain and uterine fibroids, Employ strategies to actively integrate current clinical evidence- and practice-based recommendations for the management of patients with endometriosis and uterine fibroids.

    • 38 min.

Top-podcasts in Wetenschap

Luisteraars hebben zich ook geabonneerd op